Literature DB >> 22244181

Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomies.

Satoshi Nara1, Kazuaki Shimada, Yoshihiro Sakamoto, Minoru Esaki, Yoji Kishi, Tomoo Kosuge, Hidenori Ojima.   

Abstract

BACKGROUND: During resection of a hepatocellular carcinoma, surgeons encounter occasionally a situation where marginal resection is inevitable because of a close association between the hepatocellular carcinoma and major vasculature and/or underlying impaired liver function. We investigated the impact of marginal resection on recurrence-free survival after a resection of a solitary hepatocellular carcinoma.
METHODS: The data of 570 patients who underwent macroscopically curative hepatectomy for a solitary hepatocellular carcinoma in our institution between 1990 and 2007 were analyzed. Marginal resection and non-marginal resection were defined as a cancer-negative surgical margin of ≤ 1 mm and a surgical margin of >1 mm, respectively. The macroscopic appearance of the hepatocellular carcinoma was classified as the simple nodular type or non-simple nodular type based on the classification of the Liver Cancer Study Group of Japan, and patients were categorized into 4 groups: group A, simple nodular type with cirrhosis; group B, simple nodular type without cirrhosis; group C, non-simple nodular type with cirrhosis; and group D, non-simple nodular type without cirrhosis.
RESULTS: The surgical margins were diagnosed as cancer-positive in 31 patients, as marginal resection in 165 patients, and as non-marginal resection in 374 patients. The marginal resection group showed a better recurrence-free survival than the positive surgical margin group (P = .001), and also a worse recurrence-free survival than the non-marginal resection group (P = .003). In groups A, B, and C, the recurrence-free survival rates were similar between marginal resection and non-marginal resection patients (P = .458), while in group D, marginal resection was a significant poor prognostic factor of recurrence-free survival in both univariate and multivariate analyses.
CONCLUSION: Marginal resection is acceptable in group A, B, and C patients, because it did not negatively affect postoperative recurrence-free survival. Copyright Â
© 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22244181     DOI: 10.1016/j.surg.2011.12.002

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  19 in total

1.  Relationship of different surgical margins with recurrence-free survival in patients with hepatocellular carcinoma.

Authors:  Weiyu Hu; Xufeng Pang; Weidong Guo; Liqun Wu; Bin Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Laparoscopic liver resection for lesions adjacent to major vasculature: feasibility, safety and oncological efficiency.

Authors:  Mohammad Abu Hilal; Marcel J van der Poel; Morsal Samim; Marc G H Besselink; David Flowers; Brian Stedman; Neil W Pearce
Journal:  J Gastrointest Surg       Date:  2015-01-07       Impact factor: 3.452

Review 3.  Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

Authors:  Gar-Yang Chau
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 4.  Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus.

Authors:  Tianfu Wen; Chen Jin; Antonio Facciorusso; Matteo Donadon; Ho-Seong Han; Yilei Mao; Chaoliu Dai; Shuqun Cheng; Bixiang Zhang; Baogang Peng; Shunda Du; Changjun Jia; Feng Xu; Jie Shi; Juxian Sun; Peng Zhu; Satoshi Nara; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

5.  The role of postoperative radiotherapy in hepatocellular carcinoma.

Authors:  Joongyo Lee; Jinsil Seong
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

Review 6.  Cancer concepts and principles: primer for the interventional oncologist-part II.

Authors:  Ryan Hickey; Michael Vouche; Daniel Y Sze; Elias Hohlastos; Jeremy Collins; Todd Schirmang; Khairuddin Memon; Robert K Ryu; Kent Sato; Richard Chen; Ramona Gupta; Scott Resnick; James Carr; Howard B Chrisman; Albert A Nemcek; Robert L Vogelzang; Robert J Lewandowski; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2013-06-28       Impact factor: 3.464

7.  Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival.

Authors:  Theodoros Michelakos; Filippos Kontos; Yurie Sekigami; Motaz Qadan; Lei Cai; Onofrio Catalano; Vikram Deshpande; Madhukar S Patel; Teppei Yamada; Nahel Elias; Leigh Anne Dageforde; Shoko Kimura; Tatsuo Kawai; Kenneth K Tanabe; James F Markmann; Heidi Yeh; Cristina R Ferrone
Journal:  J Gastrointest Surg       Date:  2020-08-10       Impact factor: 3.452

8.  R1 hepatectomy with exposure of tumor surface for centrally located hepatocellular carcinoma.

Authors:  Weibo Yu; Weiqi Rong; Liming Wang; Fan Wu; Quan Xu; Jianxiong Wu
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

9.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).

Authors:  Jian Zhou; Hui-Chuan Sun; Zheng Wang; Wen-Ming Cong; Jian-Hua Wang; Meng-Su Zeng; Jia-Mei Yang; Ping Bie; Lian-Xin Liu; Tian-Fu Wen; Guo-Hong Han; Mao-Qiang Wang; Rui-Bao Liu; Li-Gong Lu; Zheng-Gang Ren; Min-Shan Chen; Zhao-Chong Zeng; Ping Liang; Chang-Hong Liang; Min Chen; Fu-Hua Yan; Wen-Ping Wang; Yuan Ji; Wen-Wu Cheng; Chao-Liu Dai; Wei-Dong Jia; Ya-Ming Li; Ye-Xiong Li; Jun Liang; Tian-Shu Liu; Guo-Yue Lv; Yi-Lei Mao; Wei-Xin Ren; Hong-Cheng Shi; Wen-Tao Wang; Xiao-Ying Wang; Bao-Cai Xing; Jian-Ming Xu; Jian-Yong Yang; Ye-Fa Yang; Sheng-Long Ye; Zheng-Yu Yin; Bo-Heng Zhang; Shui-Jun Zhang; Wei-Ping Zhou; Ji-Ye Zhu; Rong Liu; Ying-Hong Shi; Yong-Sheng Xiao; Zhi Dai; Gao-Jun Teng; Jian-Qiang Cai; Wei-Lin Wang; Jia-Hong Dong; Qiang Li; Feng Shen; Shu-Kui Qin; Jia Fan
Journal:  Liver Cancer       Date:  2018-06-14       Impact factor: 11.740

10.  Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Authors:  Jian Zhou; Huichuan Sun; Zheng Wang; Wenming Cong; Jianhua Wang; Mengsu Zeng; Weiping Zhou; Ping Bie; Lianxin Liu; Tianfu Wen; Guohong Han; Maoqiang Wang; Ruibao Liu; Ligong Lu; Zhengang Ren; Minshan Chen; Zhaochong Zeng; Ping Liang; Changhong Liang; Min Chen; Fuhua Yan; Wenping Wang; Yuan Ji; Jingping Yun; Dingfang Cai; Yongjun Chen; Wenwu Cheng; Shuqun Cheng; Chaoliu Dai; Wenzhi Guo; Baojin Hua; Xiaowu Huang; Weidong Jia; Yaming Li; Yexiong Li; Jun Liang; Tianshu Liu; Guoyue Lv; Yilei Mao; Tao Peng; Weixin Ren; Hongcheng Shi; Guoming Shi; Kaishan Tao; Wentao Wang; Xiaoying Wang; Zhiming Wang; Bangde Xiang; Baocai Xing; Jianming Xu; Jiamei Yang; Jianyong Yang; Yefa Yang; Yunke Yang; Shenglong Ye; Zhengyu Yin; Bixiang Zhang; Boheng Zhang; Leida Zhang; Shuijun Zhang; Ti Zhang; Yongfu Zhao; Honggang Zheng; Jiye Zhu; Kangshun Zhu; Rong Liu; Yinghong Shi; Yongsheng Xiao; Zhi Dai; Gaojun Teng; Jianqiang Cai; Weilin Wang; Xiujun Cai; Qiang Li; Feng Shen; Shukui Qin; Jiahong Dong; Jia Fan
Journal:  Liver Cancer       Date:  2020-11-11       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.